Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.33 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.33 |
| ▸ | HTR3A | P46098 | 1/20 | 0.33 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.33 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8260874 | 0.76 | TDP1 (0.36) | TDP1SLC6A2SLC6A4HTR3AKCNH2 | |
| SCHEMBL16394631 | 0.74 | TDP1 (0.42) | TDP1SLC6A2SLC6A4HTR3AKCNH2 | |
| Hydrochloric Acid SCHEMBL27035712 | 0.74 | TDP1 (0.47) | TDP1SLC6A2SLC6A4HTR3AKCNH2 | |
| Hydrochloric Acid SCHEMBL796426 | 0.72 | TDP1 (0.46) | TDP1SLC6A2SLC6A4HTR3AKCNH2 | |
| Nitric Acid SCHEMBL9344153 | 0.72 | TDP1 (0.33) | TDP1SLC6A2SLC6A4HTR3AKCNH2 | |
| SCHEMBL17318288 | 0.69 | NOS3 (0.39) | TDP1SLC6A4 | |
| SCHEMBL20071877 | 0.69 | TDP1 (0.39) | TDP1SLC6A2SLC6A4HTR3AKCNH2 | |
| SCHEMBL27166390 | 0.69 | TDP1 (0.39) | TDP1SLC6A2SLC6A4HTR3AKCNH2 | |
| SCHEMBL91544 | 0.69 | TDP1 (0.43) | TDP1SLC6A2SLC6A4HTR3AKCNH2 | |
| SCHEMBL13743087 | 0.68 | TDP1 (0.36) | TDP1SLC6A2SLC6A4HTR3AKCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090215838-A1 | ORGANIC NITRIC OXIDE ENHANCING SALTS OF ANGIOTENSIN II ANTAGONISTS, COMPOSITIONS AND METHODS OF USE | NITROMED, INC. (US) | 2009-08-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090215838-A1 | ORGANIC NITRIC OXIDE ENHANCING SALTS OF ANGIOTENSIN II ANTAGONISTS, COMPOSITIONS AND METHODS OF USE | NOS2, NOS3, NOS1 | TDP1 2230/4885SLC6A2 279/4885SLC6A4 993/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.